CRISPR Therapeutics Reports Q1 2026 Financial Results with Revenue Increase to $1.5 Million

CRISPR Therapeutics AG reported its financial results for the first quarter of 2026, revealing a total revenue of $1.5 million, a significant increase from $865,000 in the same period last year. The revenue comprised $1,000 from collaboration activities and $458.9 million in grant revenue. The company’s operating expenses decreased to $131.7 million from $149.3 million year-over-year, primarily due to reduced research and development costs and lower collaboration expenses. As a result, CRISPR Therapeutics recorded a net loss of $122.9 million, an improvement from the $136.0 million loss reported in the first quarter of 2025.

The company’s cash and cash equivalents rose to $423.3 million as of March 31, 2026, compared to $347.6 million at the end of 2025. Additionally, marketable securities increased to $2.0 billion from $1.6 billion over the same period. The total assets of CRISPR Therapeutics reached $2.7 billion, up from $2.3 billion at the end of the previous fiscal year. The increase in cash and marketable securities was bolstered by the issuance of $600 million in convertible senior notes in March 2026, which provided net proceeds of approximately $585.4 million.

Operationally, CRISPR Therapeutics continues to advance its gene-editing programs, particularly in hemoglobinopathies with its lead product, CASGEVY, which has received regulatory approvals in multiple regions. The company is also expanding its collaboration with Vertex Pharmaceuticals, focusing on the development of therapies for sickle cell disease and transfusion-dependent beta-thalassemia. The collaboration expenses related to this partnership decreased to $45.9 million from $57.5 million, reflecting a more favorable cost-sharing arrangement.

In terms of workforce, CRISPR Therapeutics reported an increase in employee headcount, which is expected to support ongoing research and development efforts. The company anticipates continued investment in its clinical programs and the development of new technologies, which may lead to increased operational costs in the future. Looking ahead, CRISPR Therapeutics expects its existing cash and marketable securities to fund operations for at least the next 24 months, although it may seek additional financing to support long-term growth and commercialization efforts. The company remains focused on advancing its innovative gene-editing technologies and expanding its therapeutic portfolio.